TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04576455
Drug: Fulvestrant or an Aromatase Inhibitor (Physician Choice)
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Physician choice of endocrine monotherapy (fulvestrant or an aromatase inhibitor) is taken in accordance with the local prescribing information for the respective product.
Study: NCT02930551
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01341964
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600mg (2 pills)
Study: NCT01341964
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325mg (1 pill)
Study: NCT01341964
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81mg (1 pill)
Study: NCT02935036
Drug: ADPS topical product
Normalized name: ADP-597
DrugBank: ADP-597 (DB12084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical product
Study: NCT03505944
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: venetoclax + lenalidomide + rituximab
Study: NCT01313676
Drug: fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100/25mcg given once daily via novel dry powder inhaler
Study: NCT01313676
Drug: fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mcg given once daily via novel dry powder inhaler
Study: NCT01313676
Drug: vilanterol
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mcg given once daily via novel dry powder inhaler
Study: NCT03312114
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab\* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)
Study: NCT03862950
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Active medication
Study: NCT04252664
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
Study: NCT04252664
Drug: Remdesivir placebo
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
Study: NCT00571714
Drug: Peginterferon alpha-2a and ribavirin
Normalized name: peginterferon alfa-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
Study: NCT00571714
Drug: Peginterferon alpha-2a , ribavirin and betaine
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
Study: NCT00597766
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
Study: NCT00597766
Drug: Triamcinolone + Lidocaine
Normalized name: lidocaine / triamcinolone
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
Study: NCT00597766
Drug: Triamcinolone + Lidocaine
Normalized name: lidocaine / triamcinolone
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
Study: NCT00597766
Drug: Triamcinolone + Lidocaine
Normalized name: lidocaine / triamcinolone
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
Study: NCT02771158
Drug: Midodrine
Normalized name: Midodrine
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
Study: NCT01909479
Drug: MOD-4023
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Individualized once weekly dose of MOD-4023
Study: NCT03348462
Drug: ethosomal preparation of anthralin
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily with short contact topical application
Study: NCT03348462
Drug: liposomal preparation of anthralin
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily with short contact topical application
Study: NCT00057512
Drug: M4N
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
Study: NCT04742023
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin will be administered.
Study: NCT00111735
Drug: Thyroxine
Normalized name: Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04403776
Drug: tofacitinib MR 11 mg
Normalized name: tofacitinib 11 MG
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
Study: NCT04403776
Drug: tofacitinib IR 5 mg
Normalized name: tofacitinib 5 MG
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.
Study: NCT01251055
Drug: GlyT-1 inhibitor-1
Normalized name: Urinary trypsin inhibitor 1
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlyT-1 inhibitor-1(500) 4# BID
Study: NCT02132260
Drug: Naftifine Hydrochloride Cream 2%
DrugBank: Naftifine (DB00735)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks
Study: NCT01692678
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.
Study: NCT01692678
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
Study: NCT02624856
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
Study: NCT02624856
Drug: Bupivacaine plus dexamethasone
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
Study: NCT06638749
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of tranexamic acid
Study: NCT02937571
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02937571
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02937571
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01328821
Drug: CTP-499
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 600 mg, 1200 mg, 1800 mg and 2400 mg
Study: NCT01328821
Drug: CTP-499
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 400 mg immediate release capsule
Study: NCT01608659
Drug: botulinum toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Previous treatment with botulinum toxin Type A for treatment of facial lines
Study: NCT00376103
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mg/m2/day
Study: NCT03962647
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg taken once daily by mouth
Study: NCT00936650
Drug: cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
Study: NCT03653546
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SoC EGFRTKI Erlotinib 150 mg PO Q.D
Study: NCT03653546
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SoC EGFRTKI Gefitinib 250 mg PO Q.D
Study: NCT02784496
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02383823
Drug: Estrogens
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crossover study of estrogen or placebo in random order in menopausal women
Study: NCT00835549
Drug: Cefdinir for oral suspension 250 mg/5mL
Normalized name: cefdinir Oral Suspension
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 250 mg/5mL, single-dose non-fasting
Study: NCT04201873
Drug: Poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM
Study: NCT02592863
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
Study: NCT05931718
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: evaluation of recombinant erythropoietin use, safety and efficacy in patients with autoimmune hemolytic anemia according to clinical practice
Study: NCT05931718
Drug: Luspatercept
Normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: evaluation of cytokine levels, molecular profile and bone marrow microenvironment by single cell analysis in patients treated with luspatercept according to clinical practice
Study: NCT05931718
Drug: Thrombopoietin Receptor Agonist
Normalized name: Thrombopoietin receptor agonist
DrugBank: Thrombopoietin (DB06534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: evaluation of TPO-RA use, safety and efficacy in patients with ITP according to clinical practice
Study: NCT05931718
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: evaluation of G-CSF use, safety and efficacy in patients with CIN/AIN according to clinical practice
Study: NCT03228732
Drug: DHEA
Normalized name: DHEA
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.
Study: NCT03453541
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
Study: NCT03396861
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival aflibercept
Study: NCT04419519
Drug: Venetoclax monotherapy
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax monotherapy
Study: NCT04419519
Drug: Venetoclax with anti CD20 monoclonal antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax with anti CD20 monoclonal antibody
Study: NCT01602913
Drug: Paroxetine alone
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
Study: NCT00180791
Drug: Etoposide, carboplatin, melphalan, cisplatin, thiotepa
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02914886
Drug: Apidra
Normalized name: Apidra
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
Study: NCT02914886
Drug: current insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
Study: NCT00001784
Drug: Mexiletine
Normalized name: Mexiletine
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03579719
Drug: Balovaptan
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20.
Study: NCT03579719
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
Study: NCT01929603
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
Study: NCT01929603
Drug: Olaparib tablet dosing
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
Study: NCT01787747
Drug: AVP-786 Dose 1
Normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01787747
Drug: AVP-786 Dose 2
Normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01787747
Drug: AVP-923
Normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02034565
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00517114
Drug: Rabeprazole 20mg twice daily
Normalized name: rabeprazole sodium 20 MG
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00778401
Drug: Gabapentin tablets 800 mg
Normalized name: gabapentin Oral Tablet
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02262663
Drug: Vilaprisan (BAY1002670)
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02553733
Drug: Beetroot juice
Normalized name: tamarind juice
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
Study: NCT02553733
Drug: Beetroot juice placebo
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
Study: NCT04597801
Drug: Alcon
Normalized name: alconox
DrugBank: Sofalcone (DB05197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.
Study: NCT02474498
Drug: EMD
Normalized name: Zemdri
DrugBank: Plazomicin (DB12615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
Study: NCT00000222
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01833078
Drug: ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ghrelin administration subcutaneously for 7 days
Study: NCT00742157
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
Study: NCT05807945
Drug: Ropivacaine 0.75% Injectable Solution
Normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.75%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
Study: NCT05807945
Drug: Ropivacaine 0.2% Injectable Solution
Normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
Study: NCT02957019
Drug: L19-IL2 - Ph I
Normalized name: L19-IL2
DrugBank: Darleukin (DB17157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
Study: NCT02957019
Drug: L19-IL2 at RD - Ph II
Normalized name: L19-IL2
DrugBank: Darleukin (DB17157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
Study: NCT02957019
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
Study: NCT01686321
Drug: Bendamustine and subcutaneous rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04426357
Drug: JNJ-64417184
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
Study: NCT04053023
Drug: GSK2330672 (linerixibat)
Normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 is available as a tablet with unit dose strength of 45 mg.
Study: NCT00437073
Drug: topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
Study: NCT00437073
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: lapatinib administered 1250mg once daily orally
Study: NCT03464201
Drug: Enzalutamide 40 MG
Normalized name: enzalutamide 40 MG
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg p.o. every day
Study: NCT00860496
Drug: CP- 690,550 and Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
Study: NCT00860496
Drug: CP- 690,550 and Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
Study: NCT04053023
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
Study: NCT02810392
Drug: Intranasal Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.